ALX ONCOLOGY HOLDINGS INC logo

ALX ONCOLOGY HOLDINGS INC

0001810182

ALX Oncology is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. They focus on innovative approaches to optimize future standards of care. Their lead therapeutic candidate, evorpacept, has demonstrated potential as a cornerstone in immuno-oncology.

80
Highly Trusted
Trust Score

Official Registry

Legal Name
ALX ONCOLOGY HOLDINGS INC
Organization Number
0001810182
VAT Number
850642577
Company Status
Active
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA 94080
Industry Codes
2834: Pharmaceutical Preparations

Last verified: 1/2/2026

AI Quality Analysis

Industry
Biotechnology
SSL/HTTPS
Secure
Professional Email
Yes
Contact Email
medinfo@alxoncology.com

🌟 Similar Trusted Businesses

Context Therapeutics Inc.

Context Therapeutics Inc. logo
86/100 · Highly Trusted

Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.

2001 MARKET STREET, USA
View Profile

AGENUS INC

AGENUS INC logo
86/100 · Highly Trusted

Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.

3 FORBES ROAD, USA
View Profile

Evaxion A/S

Evaxion A/S logo
77/100 · Trusted

Evaxion utilizes its AI-Immunology™ platform to challenge and improve standardized treatments. In oncology, they create personalized therapies, tailoring treatment to the individual. For infectious diseases, they design next-generation vaccines to address unmet medical needs. Their AI platform accelerates vaccine target discovery, design, and development.

DR NEERGAARDS VEJ 5F, USA
View Profile